Efgartigimod is one of the new molecules used in refractory forms of myasthenia gravis. Chinese researchers have reviewed the side effects recorded in the Food and Drug Administration (FDA) pharmacovigilance database, which is freely accessible in the United States:
- the study covered the period from the first quarter of 2022 to the fourth quarter of 2023,
- a total of 1,403 adverse events were recorded,
- mainly involving headaches, infectious episodes, cases of atrial fibrillation, and transient ischemic attacks (TIAs),
- some of which had not been observed in clinical trials prior to marketing authorization.
The authors emphasize the imperfection and incompleteness of this database (FAERS) due to its purely declarative nature. However, the overall tolerance of efgartigimod in this indication appears to be very acceptable.
Â
